Staidson Beijing Biopharma (300204) - Total Assets

Latest as of March 2026: CN¥1.28 Billion CNY ≈ $187.45 Million USD

Based on the latest financial reports, Staidson Beijing Biopharma (300204) holds total assets worth CN¥1.28 Billion CNY (≈ $187.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Staidson Beijing Biopharma investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Staidson Beijing Biopharma - Total Assets Trend (2007–2025)

This chart illustrates how Staidson Beijing Biopharma's total assets have evolved over time, based on quarterly financial data. Explore how much of Staidson Beijing Biopharma's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Staidson Beijing Biopharma - Asset Composition Analysis

Current Asset Composition (December 2025)

Staidson Beijing Biopharma's total assets of CN¥1.28 Billion consist of 20.0% current assets and 80.1% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	9.8%
Accounts Receivable	CN¥24.13 Million	1.9%
Inventory	CN¥19.30 Million	1.5%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥222.33 Million	17.6%
Goodwill	CN¥19.75 Million	1.6%

Asset Composition Trend (2007–2025)

This chart illustrates how Staidson Beijing Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Staidson Beijing Biopharma market cap and net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Staidson Beijing Biopharma's current assets represent 20.0% of total assets in 2025, a decrease from 46.7% in 2007.
Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 16.1% in 2007.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 24.0% in 2007.
Asset Diversification: The largest asset category is intangible assets at 17.6% of total assets.

Staidson Beijing Biopharma Competitors by Total Assets

Key competitors of Staidson Beijing Biopharma based on total assets are shown below.

Company	Country	Total Assets
Ascendis Pharma AS NASDAQ:ASND	USA	$2.01 Billion
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$8.59 Billion
Spyre Therapeutics Inc. NASDAQ:SYRE	USA	$763.95 Million
3SBio Inc F:83B	Germany	€36.25 Billion
Soleno Therapeutics Inc NASDAQ:SLNO	USA	$608.39 Million
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	China	CN¥4.48 Billion
Novavax Inc NASDAQ:NVAX	USA	$1.04 Billion
BB Biotech AG SW:BION	Switzerland	CHF2.64 Billion

Staidson Beijing Biopharma - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.00	1.59	4.92
Quick Ratio	1.85	1.40	4.75
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥131.32 Million	CN¥83.76 Million	CN¥619.94 Million

Staidson Beijing Biopharma - Advanced Valuation Insights

This section examines the relationship between Staidson Beijing Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	12.02
Latest Market Cap to Assets Ratio	1.13
Asset Growth Rate (YoY)	10.1%
Total Assets	CN¥1.27 Billion
Market Capitalization	$1.43 Billion USD

Valuation Analysis

Above Book Valuation: The market values Staidson Beijing Biopharma's assets above their book value (1.13x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Staidson Beijing Biopharma's assets grew by 10.1% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Staidson Beijing Biopharma (2007–2025)

The table below shows the annual total assets of Staidson Beijing Biopharma from 2007 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥1.27 Billion ≈ $185.29 Million	+10.14%
2024-12-31	CN¥1.15 Billion ≈ $168.22 Million	-13.71%
2023-12-31	CN¥1.33 Billion ≈ $194.95 Million	-20.19%
2022-12-31	CN¥1.67 Billion ≈ $244.27 Million	-8.63%
2021-12-31	CN¥1.83 Billion ≈ $267.35 Million	-1.57%
2020-12-31	CN¥1.86 Billion ≈ $271.62 Million	-0.33%
2019-12-31	CN¥1.86 Billion ≈ $272.53 Million	-32.82%
2018-12-31	CN¥2.77 Billion ≈ $405.65 Million	+5.46%
2017-12-31	CN¥2.63 Billion ≈ $384.64 Million	+11.82%
2016-12-31	CN¥2.35 Billion ≈ $343.97 Million	+13.51%
2015-12-31	CN¥2.07 Billion ≈ $303.03 Million	+14.29%
2014-12-31	CN¥1.81 Billion ≈ $265.14 Million	+15.45%
2013-12-31	CN¥1.57 Billion ≈ $229.66 Million	+9.53%
2012-12-31	CN¥1.43 Billion ≈ $209.69 Million	+24.67%
2011-12-31	CN¥1.15 Billion ≈ $168.19 Million	+333.93%
2010-12-31	CN¥264.88 Million ≈ $38.76 Million	+78.07%
2009-12-31	CN¥148.75 Million ≈ $21.77 Million	+61.57%
2008-12-31	CN¥92.07 Million ≈ $13.47 Million	+11.98%
2007-12-31	CN¥82.22 Million ≈ $12.03 Million	--

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.43 Billion

CN¥9.79 Billion CNY

Market Cap Rank

#7556 Global

#1757 in China

Share Price

CN¥20.50

Change (1 day)

+1.94%

52-Week Range

CN¥20.11 - CN¥61.00

All Time High

CN¥61.00